Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

690 - Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)


20 Dec 2015


Poster presentation 2


Chao Su Hu


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


C.S. Hu1, A. Chan2, L. Gao3, M.A. Ahn4, E.E.W. Cohen5, M.K. Ang6, Y. Cheng7, Q. Hu8, S.B. Kim9, P. Li10, Y. Sun11, B. Fan12, G. Cheng13, E. Ehrnrooth14, C. Wang15

Author affiliations

  • 1 Shanghai Cancer Center, Fudan University, 200032 - Shanghai/CN
  • 2 Sir Yk Pao Centre For Cancer, The Chinese University of Hong Kong, Hong Kong/CN
  • 3 Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing/CN
  • 4 Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul/KR
  • 5 Department Of Medicine, University of California San Diego Moores Cancer Center, La Jolla/US
  • 6 Department Of Medical Oncology, National Cancer Center, Singapore/SG
  • 7 Division Of Thoracic Oncology, The Tumor Hospital of Jilin Province, Changchun/CN
  • 8 Head And Neck Cancer Center, Zhejiang Cancer Hospital, Hangzhou/CN
  • 9 Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 10 West China Hospital, Sichuan University, Sichuan/CN
  • 11 School Of Oncology, Peking University Cancer Hospital, Beijing/CN
  • 12 Medical, Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai/CN
  • 13 Biometrics & Data Management, Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai/CN
  • 14 Ta Oncology, Boehringer Ingelheim, Danmark A/S/DK
  • 15 Department Of Cancer Center, Chang Gung Memorial Hospital - Keelung, Taipei/TW


Abstract 690


Following curatively intended CRT, the standard of care for LA HNSCC is observation, and recurrence is common. In a Phase III trial in patients with recurrent and/or metastatic HNSCC progressing on/after platinum-based therapy, afatinib, an irreversible ErbB family blocker, significantly improved progression-free survival and health-related quality of life (HRQoL) vs methotrexate (Machiels, Lancet Oncol 2015). The LUX-H&N2 (global) and LUX-H&N4 (Asia) trials investigate afatinib as adjuvant therapy following CRT in patients with primary unresected LA HNSCC; LUX-H&N4 is described here.

Trial design

Phase III, double-blind, placebo-controlled, randomized study evaluating efficacy and safety of adjuvant afatinib vs placebo after CRT in patients with primary unresected LA HNSCC (NCT02131155). Key eligibility criteria: age ≥18 yrs; ECOG PS of 0 or 1; histologically or cytologically confirmed LA HNSCC; unresected tumor prior to CRT; definitive platinum-based CRT completed ≤24 wks before randomization; no evidence of disease following CRT; unfavorable risk of recurrence (defined as non-oropharynx primary site or oropharynx cancer in heavy smokers [>10 pack yrs]). Exclusion criteria include: base of tongue/tonsil cancer and ≤10 pack yrs smoking history; cancer of nasopharynx, sinuses or salivary glands; prior treatment with EGFR-targeted small molecules/antibodies or investigational agents for HNSCC. Patients are randomized 2:1 to afatinib (40 mg/d orally) or placebo, and will receive continuous treatment for 80 wks or until tumor recurrence/second primary tumor or unacceptable adverse events (AEs). Afatinib must be escalated to 50 mg after ≥4 wks with minimal drug-related AEs, or reduced by 10 mg decrements to a minimum of 20 mg in case of drug-related grade ≥3 or selected grade 1/2 AEs. The primary endpoint is disease-free survival (DFS); secondary endpoints include DFS rate at 2 yrs, overall survival, HRQoL, and safety. Target enrollment is 150 patients; recruitment is ongoing in China, Republic of Korea, Taiwan and Singapore.

Clinical trial identification



A. Chan: advisory board involvement with Merck and Pfizer and research funding from Merck, Eli Lilly, Boehringer Ingelheim and Amgen. M.-J. Ahn: involvement with advisory boards for BMS, ARIAD and Lilly. E. Cohen: advisory board involvement with Merck and Pfizer and honoraria from Eisai and Bayer. B. Fan, G. Cheng, E. Ehrnrooth: employment by Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings